February 7, 2013
11:00 am – 12:00 pm EST

Sponsored by:

Soma Logic

Symposium Course Description:

We have analyzed the proteomics of >3500 samples from a range of pulmonary diseases, including non-small cell lung cancer (NSCLC), lymphangioleiomyomatosis (LAM), acute lung injury (ALI), cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). In this symposium we will present data and results from these studies that demonstrate the utilization of proteomics to better understand biology, diagnosis, and treatment of lung disorders.

Learning Objectives:

  • Proteomic study designs for diseases of the lung
  • Results, physiology and biology for several proteomic studies of lung diseases
  • How unbiased approaches to measuring proteins work
  • The utility of proteomics for advancing knowledge

Who Should Attend:

Researchers and scientists in:

  • Translational medicine
  • Biomarker discovery
  • Respiratory drug discovery or development
  • Pulmonology

Program Agenda:

11:00–11:15 am - NSCLC, Rachel Ostroff
11:15–11:35 am - COPD, LAM, CF, ALI, Steve Williams
11:35–11:45 am - The Technology, Nick Saccomano
11:45 am–12:00 pm - Q&A

Speaker Information:

Stephen WilliamsStephen Williams, MD, PhD; Chief Medical Officer, SomaLogic; swilliams@somalogic.com

Steve Williams joined SomaLogic in 2009 as chief medical officer. Steve trained as a physician at Charing Cross and Westminster medical school, University of London, and following his internships, returned to the same institution for a Ph.D. in medicine and physiology. He subsequently performed three years of residency in diagnostic imaging at the University of Newcastle upon Tyne. He joined Pfizer in the U.K. in 1989 in experimental medicine, and worked on a variety of programs including asthma, irritable bowel syndrome, migraine [eletriptan], depression [sertraline] and urinary incontinence [darifenacin]. He moved to the U.S. in 1993 with Pfizer and worked in inflammatory bowel disease, stroke, psychosis [ziprasidone] and head injury. He created the clinical technology group in 1997, which became a worldwide function on five research sites with the objective of validating clinical biomarkers and measurements, and was made vice president in 2006. In process initiatives, he led or co-led initiatives in diagnostics, biomarkers, quality of drug candidates, and guidelines for development teams to make the decision to start Phase III trials.

Rachel OstroffRachel Ostroff, PhD; Director, Clinical Research, SomaLogic; rostroff@somalogic.com

Nick Saccomano joined SomaLogic in 2009. Nick obtained his Ph.D. in chemistry from Columbia University in 1984 under the direction of Professor Gilbert Stork. In 1984, he joined Pfizer Inc. as a research scientist in the CNS discovery group. Between 1985 and 1998, he held several positions in this group, including head of medicinal chemistry. During this time, Nick worked on or led many programs targeting psychiatric and neurological indications including depression, anxiety, psychosis, sleep, stroke, Parkinson's disease, and Alzheimer's disease. In 1998, he was promoted to vice president of discovery technology. In this role, Nick managed and developed a diverse set of enabling technologies used broadly across the drug discovery process within Pfizer. In 2004, Nick was promoted to senior vice president of global research technology and strategic alliances. In 2008, he moved to Bend Research Inc. as chief scientific officer, and he remains a member of the Board of Directors of this organization.

Nick SaccomanoNick Saccomano, PhD; Chief Technology Officer, SomaLogic; nsaccomano@somalogic.com

Rachel joined SomaLogic in 2001. Rachel received her PhD in microbiology and immunology from the University of Colorado where she studied pathogenic mechanisms of Pseudomonas aeruginosa. Following a post-doctoral fellowship studying the molecular biology of cell cycle regulation, Rachel joined BioStar, Inc. as a research scientist and developed rapid point of care infectious disease tests for the pediatrics and women’s health markets. As Clinical Research Director at SomaLogic, Rachel is responsible for developing clinical oncology programs beginning with biomarker discovery and continuing through validation and commercialization. She has led successful programs in early detection of many malignancies, including lung cancer, mesothelioma and pancreatic cancer. Other areas of interest include risk prediction models and utilizing SOMAscan technology to develop novel tools for translational oncology research.